The feasibility of targeting the disease-associated genes was supported by the use of Irf7 siRNA therapy, which inhibited the disease response in the kidneys of susceptible Irf3−/− mice [3], and of a recombinant IL-1 receptor antagonist (IL-1RA) [2], which inhibited acute cystitis in Asc−/− mice by blocking the hetero-dimerization of the IL-1 receptor and its accessory proteins (IL-1R1 and IL-1RAcP) [10]. Here, PYCARD is linked to cystitis.